Oxford BioDynamics (LON:OBD) Trading Up 14% – Still a Buy?

Oxford BioDynamics Plc (LON:OBD)’s stock price traded up 14% during mid-day trading on Thursday . The stock traded as high as GBX 0.60 ($0.01) and last traded at GBX 0.57 ($0.01). 34,066,758 shares changed hands during trading, an increase of 12% from the average session volume of 30,503,400 shares. The stock had previously closed at GBX 0.50 ($0.01).

Oxford BioDynamics Stock Up 15.0 %

The company has a market capitalization of £10.84 million, a price-to-earnings ratio of -0.10 and a beta of 0.42. The company has a debt-to-equity ratio of 370.22, a current ratio of 0.68 and a quick ratio of 2.80. The firm’s fifty day moving average price is GBX 0.85 and its 200-day moving average price is GBX 2.50.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.